L&G Pharma Breakthrough UCITS ETF | BIOTRegister to Unlock Ratings |
Performance History | 30/09/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 23.2 | -3.0 | 4.4 | -15.3 | -2.2 | |
+/-Cat | -2.8 | 6.1 | 12.3 | -14.0 | -0.9 | |
+/-B’mrk | -9.8 | -3.3 | 2.0 | -22.7 | -9.0 | |
Category: Sector Equity Biotechnology | ||||||
Category Benchmark: Morningstar Gbl Biotechnolo... |
Key Stats | ||
Closing Price 04/10/2024 | USD 10.66 | |
Day Change | 0.29% | |
Morningstar Category™ | Sector Equity Biotechnology | |
Volume | 3 | |
Exchange | LONDON STOCK EXCHANGE, THE | |
ISIN | IE00BF0H7608 | |
Fund Size (Mil) 04/10/2024 | USD 18.22 | |
Share Class Size (Mil) 04/10/2024 | USD 18.22 | |
Ongoing Charge 14/02/2024 | 0.49% |
Investment Objective: L&G Pharma Breakthrough UCITS ETF | BIOT |
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
- - | ||
Inception Date 18/01/2018 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
Solactive Pharma Breakthrough V NR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for L&G Pharma Breakthrough UCITS ETF | BIOT | 04/10/2024 |
|
|
Top 5 Holdings | Sector | % |
InnoCare Pharma Ltd | Healthcare | 3.63 |
BeiGene Ltd ADR | Healthcare | 3.50 |
Xeris Biopharma Holdings Inc | Healthcare | 3.19 |
Pharma Mar SA | Healthcare | 3.06 |
LG Chem Ltd | Basic Materials | 3.03 |
Increase Decrease New since last portfolio | ||
L&G Pharma Breakthrough UCITS ETF | BIOT |